Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
October 31, 2018
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2025
Conditions
HER2-positive Breast Cancer
Interventions
DRUG
Capecitabine
observation
All Listed Sponsors
lead
Shandong Cancer Hospital and Institute
OTHER
NCT03684863 - Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy | Biotech Hunter | Biotech Hunter